Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

Delayed Quote. Delayed  - 02/09 10:37:31 am
60.67 USD   -0.08%
10:21a BRISTOL MYERS S : Meet Biff: A Cancer Clinical Trial Patient
04:18a BRISTOL MYERS S : receives approval from US FDA for Daklinza hepatit..
02/08 BRISTOL MYERS S : FDA approves expanded use of Daklinza in HCV genot..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/03/2016 02/04/2016 02/05/2016 02/08/2016 02/09/2016 Date
60.12(c) 59.7(c) 59.63(c) 60.72(c) 60.67 Last
11 153 896 7 987 211 7 129 501 10 656 014 1 141 932 Volume
+2.12% -0.70% -0.12% +1.83% -0.08% Change
More quotes
Financials ($)
Sales 2016 17 630 M
EBIT 2016 4 351 M
Net income 2016 3 843 M
Finance 2016 1 104 M
Yield 2016 2,55%
Sales 2017 19 711 M
EBIT 2017 5 826 M
Net income 2017 4 923 M
Finance 2017 3 117 M
Yield 2017 2,62%
P/E ratio 2016 26,26
P/E ratio 2017 20,63
EV / Sales 2016 5,68x
EV / Sales 2017 4,98x
Capitalization 101 298 M
More Financials
Company
Bristol-Myers Squibb Co. is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products.Its pharmaceutical products include chemically-synthesized drugs or small molecules and an increasing portion of products produced from... 
Sector
Pharmaceuticals
Calendar
02/10 | 01:25pmPresentation
More about the company
Surperformance© ratings of Bristol-Myers Squibb Co
Trading Rating : Investor Rating :
More Ratings
Latest news on BRISTOL-MYERS SQUIBB CO
10:21a BRISTOL MYERS SQUIBB : Meet Biff: A Cancer Clinical Trial Patient
04:18a BRISTOL MYERS SQUIBB : receives approval from US FDA for Daklinza hepatitis C tr..
02/08 BRISTOL MYERS SQUIBB : FDA approves expanded use of Daklinza in HCV genotypes 1 ..
02/05 BRISTOL MYERS SQUIBB : U.S. FDA Approves Expanded Use of Bristol-Myers Squibb&rs..
02/04 BRISTOL MYERS SQUIBB : Researchers at Bristol-Myers Squibb Release New Data on L..
02/04 BRISTOL MYERS SQUIBB : CheckMate -141, a Pivotal Phase 3 Opdivo nivolumab Head a..
02/04 BRISTOL MYERS SQUIBB : Researchers from Bristol-Myers Squibb Discuss Findings in..
02/04 BRISTOL MYERS SQUIBB : Findings on Immunoglobulins Reported by Investigators at ..
More news
Sector news : Pharmaceuticals - NEC
10:49a SANOFI : and Positive Planet Partnership Promote Access to Care and Quality of H..
10:30a AUROBINDO PHARMA : Q3 net profit at Rs. 535 crore
10:02a JOHNSON & JOHNSON : to Participate in RBC Capital Markets Global Healthcare Conf..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02:56a Tracking Kahn Brothers Portfolio - Q4 2015 Update
02/08 TapImmune Tackles Ovarian Cancer In Fast Track Phase II Clinical Trials
02/05 Upcoming Events - Bayer's Lung Cancer Effort And Apricus And Zealand Try Agai..
02/05 FDA clears expanded use of Bristol-Myers' HCV med Daklinza
02/03 MY NEWEST SWEET REIT PURCHASES : Welltower And National Health Investors


Comments 
Advertisement
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions